Cellectis Presents Lasme-cel Phase 1 Data Showing Manageable Safety Profile With CRS Grade 3 In 4% Of Patients And Eti-cel Achieving 63% Complete Response In r/r B-NHL

Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the

Cellectis shares are trading higher after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to lasmecabtagene timgedleucel

Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug